Endovascular Engineering, Inc. appears in FDA records as the applicant for a single 510(k) clearance in the supplied collection, K261800, decided September 3, 2026. The company describes itself on its own site as a venture-backed developer of clot removal technologies targeting venous thromboembolism. Its public materials name two product identities: the Helo Max Thrombectomy System cleared under K261800 and the Hēlo Thrombectomy System (HEL1595) covered in an instructions-for-use summary. [1][2][6]
The K261800 clearance and its scope
K261800 covers the Helo Max Thrombectomy System (HEL2090) under product code QEW, regulation number 870.5150 (Embolectomy Catheter), Class II, with a Substantially Equivalent decision dated September 3, 2026. The FDA record lists Endovascular Engineering as applicant at 3925 Bohannon Dr., Suite 300, Menlo Park, California, and describes the device as peripheral mechanical thrombectomy with aspiration in the cardiovascular specialty. The clearance letter names both QEW and KRA product codes. [1][2]
The letter states that testing indicated the Helo Max performs as intended, conducted against design inputs, risk management input, national and international standards, and FDA feedback. Listed testing covered simulated use, tensile, torque, flow rate, clot aspiration, corrosion, heat generation, particulate and radial force. Sterilization validation was performed per ISO 11135 with a stated sterility assurance level of 10-6. [2]
The Hēlo platform as published
A brief instructions-for-use summary describes the Hēlo 15F Thrombectomy System (HEL1595) as a minimally invasive aspiration system for removing thromboembolic material from the pulmonary arteries, indicated for non-surgical removal of emboli and thrombi from pulmonary arteries and venous vasculature. The same document instructs users not to place the suction canister more than 12 inches above the patient to avoid backflow, and notes federal law restricts sale to or on the order of a physician. [3]
The company's product page describes the Hēlo Thrombectomy System as dual-action technology for clot removal and carries a quoted comment attributed to Taisei Kobayashi, MD, about combining large- and small-bore embolectomy. That quotation is a clinician statement published by the company, not an independent finding. [7]
Company positioning and clinical framing
Endovascular Engineering describes itself as a mission-driven, venture-backed company developing next-generation clot removal technologies for venous thromboembolism, led by engineers, clinicians and medical device leaders working with clinical partners. These are the company's own characterizations, published on its About page. [6]
Company pages state that venous thromboembolism is the third leading cause of cardiovascular death after heart attack and stroke, with roughly 10 million cases annually worldwide and pulmonary embolism responsible for most VTE-related deaths, citing Di Nisio et al. (Lancet, 2016) and Goldhaber and Bounameaux (Lancet, 2012). The clinical overview page also references the ENGULF clinical program and results presented by Dr. Andrew J. Klein at SCAI 2026 for patients treated with blood return (n=40); those figures are not reproduced here. [5][9]
What the record does and does not establish
The supplied collection contains one linked 510(k) record, K261800, with a single SESE decision; that count reflects the retrieved filings as of the snapshot and is not a measure of total portfolio, sales or safety performance. A separate openFDA query response reports a total of four results for the applicant, but its listed entries are not itemized in the public information, so additional clearances cannot be described. [1][8]
No parent company, brand ownership, customer list, commercial availability or independent efficacy data is verified in these sources. The Menlo Park address appears as the FDA filing address and the manufacturer address in the IFU summary; it is not established here as a corporate headquarters. [2][3]

